A new therapeutic strategy against cancer: cAMP elevating drugs and leptin

Cancer Biology and Therapy

Volumn 8, Issue 12, 2009, Pages 1191-1193

  Vitale, Giovanni ^a,b   Dicitore, Alessandra ^b   Mari, Daniela ^a,b   Cavagnini, Francesco ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Apoptosis; cAMP; Cancer; Cell cycle; Leptin; Protein kinase A

Indexed keywords

CASPASE 3; CYCLIC AMP; LEPTIN; PROTEIN BAD; PROTEIN BCL 2; STAT PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CARCINOGENESIS; CELL CYCLE ARREST; CELL PROLIFERATION; HUMAN; NOTE; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

EID: 68049137870     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.12.8937     Document Type: Note

References (24)

1. Robinson-White A, Stratakis CA. Protein kinase A signaling: "cross talk" with other pathways in endocrine cells. Ann NY Acad Sci 2002; 968:256-70.
2. Robinson-White A, Hundley TR, Shiferaw M, Bertherat J, Sandrini F, Stratakis CA. Protein kinase-A activity in PRKAR1A-mutant cells, and regulation of mitogen-activated protein kinases ERK1/2. Hum Mol Genet 2003; 12:1475-84.
3. Tasken K, Shalhegg BS, Tasken KA, Solberg R, Knutsen HK, Levy FO, et al. Structure, function and regulation of human cAMP-dependent protein kinase. Adv Second Messenger Prosphoprotein Res 1997; 31:191-204.
4. Scott JD. Cyclic nucleotide-dependent protein kinase. Pharmacol Ther 1991; 50:123-45.
5. Robinson-White AJ, Leitner WW, Aleem E, Kaldis P, Bossis I, Stratakis CA. PRKAR1A inactivation leads to increased proliferation and decreased apoptosis in human B lymphocytes. Cancer Res 2006; 66:10603-12.
6. Tortora G, Ciardiello F. Protein kinase A as target for novel integrated strategies of cancer therapy. Ann NY Acad Sci 2002; 968:139-47.
7. Katsaros D, Tortora G, Tagliaferri P, Clair T, Ally S, Neckers L, et al. Site-selective cyclic AMP analogs provide a new approach in the control of cancer cell growth. FEBS Lett 1987; 223:97-103.
8. Kim SN, Ahn YH, Kim SG, Park SD, Cho-Chung YS, Hong SH. 8-Cl-cAMP induces cell cycle-specific apoptosis in human cancer cells. Int J Cancer 2001; 93:33-41.
9. Cho-Chung YS, Clair T, Bodwin JS, Berghoffer B. Growth arrest and morphological change of human breast cancer cells by dibutyryl cyclic AMP and L-arginine. Science 1981; 214:77-9.
10. Ahn YH, Jung JM, Hong SH. 8-Chloro-cyclic AMP-induced growth inhibition and apoptosis is mediated by p38 mitogen-activated protein kinase activation in HL60 cells. Cancer Res 2005; 65:4896-901.
11. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 2006; 109:366-98.
12. Cho-Chung YS, Clair T, Tagliaferri P, Ally S, Katsaros D, Tortora G, et al. Site-selective cyclic AMP analogs as new biological tools in growth control, differentiation and protooncogene regulation. Cancer Invest 1989; 7:161-77.
13. Carlson CC, Burnham LL, Shanks RA, Dransfield DT. 8-Cl-adenosine induces differentiation in LS174T cells. Dig Dis Sci 2001; 46:757-64.
14. Wang HM, Zheng NG, Wu JL, Gong CC, Wang YL. Dual effects of 8-Br-cAMP on differentiation and apoptosis of human esophageal cancer cell line Eca-109. World J Gastroenterol 2005; 11:6538-42.
15. Yokozaki H, Tortora G, Pepe S, Maronde E, Genieser HG, Jastorff B, et al. Unhydrolyzable analogues of adenosine 30:50-monophosphate demonstrating growth inhibition and differentiation in human cancer cells. Cancer Res 1992; 52:2504-8.
16. Rohlff C, Clair T, Cho-Chung YS. 8-Cl-cAMP induces truncation and downregulation of the Riα subunit and upregulation of the RIIβ subunit of cAMP-dependent protein kinase leading to type II holoenzyme-dependent growth inhibition and differentiation of HL-60 leukemia cells. J Biol Chem 1993; 268:5774-82.
17. Bianco C, Tortora G, Baldassarre G, Caputo R, Fontanini G, Chinè S, et al. 8-Chloro-cAMP inhibits autocrine and angiogenic growth factors production in human colorectal and breast cancer. Clin Cancer Res 1997; 3:439-48.
18. del Valle-Pérez B, Martínez-Estrada OM, Vilaró S, Ventura F, Viñals F. cAMP inhibits TGFbeta1-induced in vitro angiogenesis. FEBS Lett 2004; 569:105-11.
19. Naviglio S, Di Gesto D, Romano M, Sorrentino A, Illiano F, Sorvillo L, et al. Leptin enhances growth inhibition by cAMP elevating agents through apoptosis of MDAMB-231 breast cancer cells. Cancer Biol Ther 2009; 8:1183-90.
20. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human omologue. Nature 1994; 372:425-32.
21. Cirillo D, Rachiglio AM, la Montagna R, Giordano A, Normanno N. Leptin signaling in breast cancer: an overview. J Cell Biochem 2008; 105:956-64.
22. Pan SY, DesMeules M. Energy intake, physical activity, energy balance and cancer: epidemiologic evidence. Methods Mol Biol 2009; 472:191-215.
23. Mark AL, Sivitz WI. Uncoupling metabolism and coupling leptin to cardiovascular disease. Arterioscler Thromb Vasc Biol 2002; 22:881-3.
24. Martin SS, Qasim A, Reilly MP. Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol 2008; 52:1201-10.